| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Randomized Controlled Trial |
| Article Title |
Amoxicillin high-dose dual therapy for Helicobacter pylori primary eradication: Proton pump inhibitor and potassium-competitive acid blocker, which’s better?
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Xue-Er Yang, Sheng-Jun Zhang, Yuan Liu, Shuo-Yi Yao, Su-Xin Zhang, Xiao-Ming Liu, Lun-Xi Liang and Fen Wang |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Natural Science Foundation of China |
82270594 |
| National Natural Science Foundation for Youths of China |
82103151 |
| Outstanding Youth Foundation of Hunan Province |
2022JJ20092 |
| Wisdom Accumulation and Talent Cultivation Project of Third Xiangya Hospital of Central South University |
YX202103 |
|
| Corresponding Author |
Fen Wang, MD, PhD, Professor, Department of Gastroenterology, the Third Xiangya Hospital, Central South University, No. 138 Tongzipo Road, Changsha 410013, Hunan Province, China. wfen-judy@csu.edu.cn |
| Key Words |
Helicobacter pylori; High-dose dual therapy; Esomeprazole; Vonoprazan; Eradication rate |
| Core Tip |
The global burden of Helicobacter pylori infection is high. Triple and quadruple therapies are both classical regimens. The effect of high-dose dual therapy (HDDT) compared to classical regimens in different regions/populations is unclear. Our study found HDDT based on vonoprazan was non-inferior to the vonoprazan triple regimen. Classical quadruple therapy had a higher eradication rate than HDDT based on esomeprazole, but in modified intention-to-treat and per-protocol analysis, EA therapy was non-inferior to B-quadruple therapy. |
| Publish Date |
2025-04-02 10:54 |
| Citation |
<p>Yang XE, Zhang SJ, Liu Y, Yao SY, Zhang SX, Liu XM, Liang LX, Wang F. Amoxicillin high-dose dual therapy for Helicobacter pylori primary eradication: Proton pump inhibitor and potassium-competitive acid blocker, which’s better? <i>World J Gastroenterol</i> 2025; 31(13): 100863</p> |
| URL |
https://www.wjgnet.com/1007-9327/full/v31/i13/100863.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v31.i13.100863 |
